Recent Changes to Clinical Prior Authorization (PA) Critera:
- Antiemetics (5HT3 Blockers): No PA required for children <15 years of age
- Antihistamines, Minimally Sedating: No clinical criteria
- Long-Acting Beta Agonists: No clinical criteria
- Leukotriene Modifiers: No clinical criteria
- Proton Pump Inhibitors: No clinical criteria for once daily therapy
- Stimulants: No diagnosis required for children age 18 or younger
(PDL requirements still exist)
Atypical Antipsychotics
Effective immediately, Idaho Medicaid is implementing the Preferred Drug List (PDL) for the Atypical Antipsychotics. The state is adopting recommendations of the Pharmacy and Therapeutics (P&T) Committee at the time of its original clinical review of this drug class. The Committee will review the class again as part of the August 2009 TOP$ review. The addition of this class to the PDL is being taken in accordance with the governor's mandated one percent budget cut (Executive Order 2008-03). As always, careful consideration has been, and will continue to be given towards ensuring Idaho Medicaid recipients have access to clinically efficacious, safe and cost-effective medications.
Idaho Medicaid Awarded Academic Detailing Grant
The Idaho Medicaid pharmacy program has been awarded a $50,000 grant to fund an academic detailing pilot program. The program, which will operate during the 2009 calendar year in southwest and south central Idaho, will provide targeted educational outreach to prescribers of mental health medications. Click Here to read more.